Search Results - "Negulescu, M."

  • Showing 1 - 13 results of 13
Refine Results
  1. 1

    Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer by Ferdinande, L, Decaestecker, C, Verset, L, Mathieu, A, Moles Lopez, X, Negulescu, A-M, Van Maerken, T, Salmon, I, Cuvelier, C A, Demetter, P

    Published in British journal of cancer (03-01-2012)
    “…Background: Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolising enzyme that induces immune tolerance by modulating T-cell responses. Carcinomas…”
    Get full text
    Journal Article
  2. 2

    Difficulties in diagnosing chronic constrictive pericarditis by Vasile, I, Negulescu, M, Florescu, G, Ionescu, R, Berbecaru, S

    Published in Netherlands heart journal (01-12-2004)
    “…This presentation calls attention to the many problems involved in the positive, aetiological and differential diagnosis of chronic constrictive pericarditis…”
    Get full text
    Journal Article Book Review
  3. 3

    Thrombosis of a popliteal pseudoaneurysm secondary to an osteochondroma of the femur: an uncommon clinical case by Negulescu, M, Arend, P

    Published in Revue médicale de Bruxelles (01-09-2014)
    “…Osteochondroma are the bone tumors most frequently found in adolescents or young adults. Most often discovered by accidental findings, they however may be…”
    Get full text
    Journal Article
  4. 4

    Les inhibiteurs MEK peuvent aussi induire des panniculites by Deilhes, F., Negulescu, M., Tournier, E., Lamant, L., Meyer, N., Sibaud, V., Boulinguez, S.

    “…Le traitement de première ligne des patients porteurs d’un mélanome avancé muté BRAFV600 repose sur l’association d’un inhibiteur BRAFV600 (vémurafénib,…”
    Get full text
    Journal Article
  5. 5

    La photo-onycholyse, une nouvelle manifestation de phototoxicité induite par le vandétanib by Negulescu, M., Baran, R., Boulinguez, S., Meyer, N., Tournier, E., Deilhes, F., Delord, J.-P., Zerdoud, S., Sibaud, V.

    “…Le vandétanib est un inhibiteur multikinase ciblant VEGFR, EGFR et le proto-oncogène RET. Cette molécule est actuellement enregistrée dans le traitement des…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13